Related Experiment Video
Updated: Mar 29, 2026
08:03
Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
Published on: June 25, 2017
20.9K
How Astragalin Modulates Glucose Uptake and Insulin Secretion in β-Cell Lines
Paola Miranda Sulis1, Alice Lima Rosa Mendes1, Paula Waiss Zanusso Bunick1
1Instituto de Bioeletricidade Celular (IBIOCEL), Ciência & Saúde, Departamento de Bioquímica, Centro de Ciência Biológicas, Universidade Federal de Santa Catarina, Florianópolis 88037-000, Brazil.
Pharmaceuticals (Basel, Switzerland)
|March 28, 2026
Summary
Astragalin, a flavonoid, boosts glucose uptake and insulin secretion in pancreatic cells by influencing potassium and calcium channels. This suggests its potential for treating type 2 diabetes mellitus (T2DM).
Area of Science:
- Endocrinology
- Molecular Biology
- Pharmacology
Background:
- Type 2 diabetes mellitus (T2DM) involves hyperglycemia and insulin resistance, impacting metabolic function.
- Flavonoids show antidiabetic promise, but their specific effects on pancreatic beta-cell ion channels and insulin release are not fully understood.
Purpose of the Study:
- To investigate astragalin's impact on glucose uptake, insulin secretion, and ionic currents in pancreatic beta-cell lines.
- To elucidate the mechanisms underlying astragalin's effects on pancreatic beta-cells.
Main Methods:
- Utilized murine MIN6 and rat INS-1 pancreatic beta-cell models.
- Quantified glucose uptake via bioluminescence and insulin secretion via ELISA.
- Analyzed ionic currents using whole-cell patch-clamp and pharmacological channel blockers (KATP, Kv, L-type Ca2+).
Main Results:
- Astragalin dose-dependently increased glucose uptake and significantly enhanced insulin secretion.
- Reduced potassium channel currents and modulated KATP, Kv, and L-type Ca2+ channels.
- Verapamil diminished the insulinotropic effect, confirming calcium influx's role in exocytosis.
Conclusions:
- Astragalin stimulates glucose uptake and insulin secretion in pancreatic beta-cells.
- Mechanism involves modulating potassium and calcium channels, facilitating calcium-dependent exocytosis.
- Astragalin shows potential as a therapeutic candidate for T2DM management.
Related Concept Videos
01:16Hormones Regulating Blood Glucose
8.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
8.4K
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:06Oral Hypoglycemic Agents: Glinides
936
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
936
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
3.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
3.1K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
852
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
852
01:28Insulin: The Receptor and Signaling Pathways
6.0K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
6.0K